CY1113636T1 - Νεος συνδυασμος για χρηση στη θεραπεια φλεγμονωδων διαταραχων - Google Patents
Νεος συνδυασμος για χρηση στη θεραπεια φλεγμονωδων διαταραχωνInfo
- Publication number
- CY1113636T1 CY1113636T1 CY20121101141T CY121101141T CY1113636T1 CY 1113636 T1 CY1113636 T1 CY 1113636T1 CY 20121101141 T CY20121101141 T CY 20121101141T CY 121101141 T CY121101141 T CY 121101141T CY 1113636 T1 CY1113636 T1 CY 1113636T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- inflammatory disorders
- new combination
- solvate
- pharmaceutically acceptable
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 abstract 1
- 229960004439 pemirolast Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87537706P | 2006-12-18 | 2006-12-18 | |
| US74307P | 2007-10-29 | 2007-10-29 | |
| EP07824625A EP2120919B1 (en) | 2006-12-18 | 2007-11-16 | New combination for use in the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113636T1 true CY1113636T1 (el) | 2016-06-22 |
Family
ID=39135213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121101141T CY1113636T1 (el) | 2006-12-18 | 2012-11-27 | Νεος συνδυασμος για χρηση στη θεραπεια φλεγμονωδων διαταραχων |
Country Status (20)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32711A (es) | 2009-06-16 | 2011-01-31 | Cardoz Ab | Nueva forma cristalina de pemirolast |
| CA2780382A1 (en) * | 2009-11-13 | 2011-05-19 | Cardoz Ab | Pemirolast for the treatment of systemic low grade inflammation |
| CN102302780B (zh) * | 2011-09-01 | 2013-05-01 | 刘树芹 | 一种治疗支气管哮喘的药物组合物 |
| CN102389418A (zh) * | 2011-09-01 | 2012-03-28 | 刘树芹 | 一种含扎鲁司特和他汀类药物的药物组合物 |
| CN102274515B (zh) * | 2011-09-01 | 2013-04-24 | 刘树芹 | 一种含孟鲁司特和他汀类药物的药物组合物 |
| CA3087344A1 (en) | 2018-01-05 | 2019-07-11 | Platelet Biogenesis, Inc. | Compositions and methods for producing megakaryocytes |
| JP2021529770A (ja) * | 2018-06-29 | 2021-11-04 | プレートレット バイオジェネシス, インコーポレイテッド | 薬物送達のための組成物およびその使用方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JP2504788B2 (ja) * | 1987-11-10 | 1996-06-05 | 東京田辺製薬株式会社 | 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤 |
| WO1995032714A1 (en) * | 1994-05-31 | 1995-12-07 | Tokyo Tanabe Company Limited | Arteriosclerosis depressant |
| WO1997045105A1 (en) * | 1996-05-24 | 1997-12-04 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| US7115278B2 (en) * | 1998-04-08 | 2006-10-03 | Theoharis C Theoharides | Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| JP2003509478A (ja) * | 1999-09-21 | 2003-03-11 | エモリー・ユニバーシティ | 血小板関連障害を処置する方法および組成物 |
| US6379684B1 (en) * | 2001-05-02 | 2002-04-30 | Alphamed Pharaceutical Corp. | Cosmetic compositions containing cromolyn compounds for revitalizing the skin |
| ITMI20011764A1 (it) * | 2001-08-10 | 2003-02-10 | Dinamite Dipharma Spa | Metodo per l'ottenimento del pemirolast ad elevata purezza |
| JPWO2004002530A1 (ja) * | 2002-06-26 | 2005-10-27 | 小野薬品工業株式会社 | 慢性疾患治療剤 |
| JP4607436B2 (ja) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | HMG−CoAリダクターゼ阻害剤を含有する医薬組成物 |
| JP4588986B2 (ja) * | 2002-08-20 | 2010-12-01 | テルモ株式会社 | 体内埋込医療器具 |
| EP1553075B1 (en) * | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| AU2004305154A1 (en) * | 2003-12-23 | 2005-07-07 | Medicure International Inc. | Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound |
| US8277831B2 (en) * | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
| US20060084695A1 (en) * | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| CA2593545A1 (en) * | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| US7202325B2 (en) * | 2005-01-14 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles |
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| US20070225301A1 (en) * | 2006-02-13 | 2007-09-27 | Astion Inflammation Aps | Treatment of acne and other diseases |
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| CA2677493A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
-
2007
- 2007-11-16 EA EA200900815A patent/EA200900815A1/ru unknown
- 2007-11-16 KR KR1020097014879A patent/KR20090106526A/ko not_active Ceased
- 2007-11-16 ES ES07824625T patent/ES2394984T3/es active Active
- 2007-11-16 SI SI200731070T patent/SI2120919T1/sl unknown
- 2007-11-16 WO PCT/GB2007/004408 patent/WO2008074975A1/en not_active Ceased
- 2007-11-16 AU AU2007336118A patent/AU2007336118A1/en not_active Abandoned
- 2007-11-16 NZ NZ577467A patent/NZ577467A/en not_active IP Right Cessation
- 2007-11-16 HR HRP20120923TT patent/HRP20120923T1/hr unknown
- 2007-11-16 MX MX2009006507A patent/MX2009006507A/es active IP Right Grant
- 2007-11-16 PT PT07824625T patent/PT2120919E/pt unknown
- 2007-11-16 CA CA002672976A patent/CA2672976A1/en not_active Abandoned
- 2007-11-16 BR BRPI0720358-6A2A patent/BRPI0720358A2/pt not_active IP Right Cessation
- 2007-11-16 EP EP07824625A patent/EP2120919B1/en active Active
- 2007-11-16 CN CNA2007800514732A patent/CN101610765A/zh active Pending
- 2007-11-16 DK DK07824625.3T patent/DK2120919T3/da active
- 2007-11-16 JP JP2009542179A patent/JP2010513430A/ja active Pending
- 2007-12-16 US US12/448,326 patent/US20100063070A1/en not_active Abandoned
-
2009
- 2009-06-02 NO NO20092134A patent/NO20092134L/no not_active Application Discontinuation
- 2009-06-07 IL IL199214A patent/IL199214A/en not_active IP Right Cessation
-
2012
- 2012-11-27 CY CY20121101141T patent/CY1113636T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL199214A0 (en) | 2010-03-28 |
| US20100063070A1 (en) | 2010-03-11 |
| HRP20120923T1 (hr) | 2012-12-31 |
| EP2120919B1 (en) | 2012-08-29 |
| DK2120919T3 (da) | 2012-11-26 |
| NZ577467A (en) | 2012-04-27 |
| JP2010513430A (ja) | 2010-04-30 |
| EA200900815A1 (ru) | 2009-12-30 |
| AU2007336118A1 (en) | 2008-06-26 |
| KR20090106526A (ko) | 2009-10-09 |
| NO20092134L (no) | 2009-09-18 |
| IL199214A (en) | 2013-04-30 |
| CN101610765A (zh) | 2009-12-23 |
| CA2672976A1 (en) | 2008-06-26 |
| MX2009006507A (es) | 2009-08-18 |
| SI2120919T1 (sl) | 2012-12-31 |
| BRPI0720358A2 (pt) | 2013-12-24 |
| EP2120919A1 (en) | 2009-11-25 |
| HK1134032A1 (en) | 2010-04-16 |
| PT2120919E (pt) | 2012-11-12 |
| WO2008074975A1 (en) | 2008-06-26 |
| ES2394984T3 (es) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301192I2 (nl) | Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan | |
| NL301176I2 (nl) | Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1120741T1 (el) | Θεραπεια οζωδους σκληρυνσης | |
| MX2009001327A (es) | Compuestos de indol. | |
| NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
| UY30500A1 (es) | Compuestos de azabencimidazolilo | |
| CY1116754T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις της comt | |
| CL2008001234A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer. | |
| UA108222C2 (xx) | СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS | |
| NL300998I1 (nl) | Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan | |
| ATE538652T1 (de) | Synergistische pharmazeutische kombination für die behandlung von krebs | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| ATE544759T1 (de) | 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon | |
| ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
| UA91848C2 (ru) | Применение соединений диосметина в лечении и предотвращении тромботическим патологиям | |
| BRPI0818267A2 (pt) | Novos derivados de 1,3-dihidro-5-isobenzofuranocarbonitrila e composição farmacêutica dos mesmos para o tratamento de ejaculação precoce | |
| NO20092134L (no) | Kombinasjonsprodukt for bruk i behandling av inflammatoriske lidelser | |
| ITRM20050446A1 (it) | Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari. | |
| UA99901C2 (en) | Indole compounds | |
| CY1111899T1 (el) | Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης | |
| ATE543501T1 (de) | Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen | |
| BRPI0812788A2 (pt) | Uso de inibidores hdac para o tratamento da destruição óssea |